DK3039040T3 - Kimær anti cd30-antigenreceptor og anvendelse deraf - Google Patents

Kimær anti cd30-antigenreceptor og anvendelse deraf Download PDF

Info

Publication number: DK3039040T3
Authority: DK; Denmark
Prior art keywords: chimary; antigen receptor; antigen; receptor; chimary anti
Prior art date: 2013-08-26

Application number

DK14756036.1T

Other languages

English (en)

Inventor

Hinrich Abken

Markus Chmielewski

Andreas Hombach

Original Assignee

Hinrich Abken

Andreas Hombach

Markus Chmielewski

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-26

Filing date

2014-08-26

Publication date

2022-02-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3039040(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-26 Application filed by Hinrich Abken, Andreas Hombach, Markus Chmielewski filed Critical Hinrich Abken

2022-02-07 Application granted granted Critical

2022-02-07 Publication of DK3039040T3 publication Critical patent/DK3039040T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4264—Cancer antigens from embryonic or fetal origin
- A61K40/4266—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Oncology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)

DK14756036.1T 2013-08-26 2014-08-26 Kimær anti cd30-antigenreceptor og anvendelse deraf DK3039040T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP13181668		2013-08-26
PCT/EP2014/068029 WO2015028444A1 (en)	2013-08-26	2014-08-26	Anti cd30 chimeric antigen receptor and its use

Publications (1)

Publication Number	Publication Date
DK3039040T3 true DK3039040T3 (da)	2022-02-07

Family

ID=49029006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14756036.1T DK3039040T3 (da)	2013-08-26	2014-08-26	Kimær anti cd30-antigenreceptor og anvendelse deraf

Country Status (7)

Country	Link
US (2)	US10808035B2 (da)
EP (2)	EP3995512A1 (da)
JP (1)	JP6285553B2 (da)
CN (1)	CN105940102B (da)
DK (1)	DK3039040T3 (da)
ES (1)	ES2905557T3 (da)
WO (1)	WO2015028444A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3169703T4 (da) *	2014-07-16	2024-02-26	Hinrich Abken	Kimær antigenreceptor og anvendelse deraf
RU2764074C2 (ru) *	2014-08-28	2022-01-13	Байоатла, Ллк	Условно активные химерные антигенные рецепторы для модифицированных т-клеток
US11111288B2 (en)	2014-08-28	2021-09-07	Bioatla, Inc.	Conditionally active chimeric antigen receptors for modified t-cells
WO2016180468A1 (en) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Claudin-18.2-specific immunoreceptors and t cell epitopes
EP3303373B1 (en)	2015-05-30	2020-04-08	Molecular Templates, Inc.	De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
CN108026151B (zh)	2015-06-19	2022-07-15	塞巴斯蒂安·科博尔德	Pd-1-cd28融合蛋白及其在医学中的用途
CN108138171B (zh) *	2015-10-08	2022-05-13	国立大学法人名古屋大学	表达嵌合抗原受体的基因修饰t细胞的制备方法
BR112018006995A2 (pt) *	2015-10-15	2018-10-30	Us Health	receptores anti-cd30 de antígeno quimérico
DK3362569T3 (da)	2015-10-16	2021-10-18	Univ Muenchen Ludwig Maximilians	Cxcr6-transducerede t-celler til målrettet tumorterapi
CA3004306A1 (en)	2015-11-04	2017-05-11	Stephen J. Forman	Chimeric antigen receptors targeting her2
EP3184548A1 (en)	2015-12-23	2017-06-28	Miltenyi Biotec GmbH	Chimeric antigen receptor with cytokine receptor activating or blocking domain
TWI844509B (zh)	2016-05-13	2024-06-11	美商拜奧亞特拉公司	抗-ror2抗體、抗體片段、其免疫結合物及其用途
CA3026858A1 (en)	2016-06-30	2018-01-04	F. Hoffmann-La Roche Ag	Improved adoptive t-cell therapy
CN106589139B (zh) *	2016-12-29	2019-10-11	武汉波睿达生物科技有限公司	一种靶向表达cd30表面抗原的细胞的嵌合抗原受体
WO2019103857A1 (en)	2017-11-22	2019-05-31	Iovance Biotherapeutics, Inc.	Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
WO2019157691A1 (zh) *	2018-02-14	2019-08-22	宜明细胞生物科技有限公司	一种重组嵌合抗原受体基因及其应用
WO2020068764A1 (en)	2018-09-24	2020-04-02	The Medical College Of Wisconsin, Inc.	Anti-cd30 antibodies and methods of use
CN109265563B (zh) *	2018-09-26	2020-01-31	武汉波睿达生物科技有限公司	一种用于治疗血液肿瘤的人源嵌合抗原受体及其应用
US20210386781A1 (en) *	2018-10-05	2021-12-16	St. Anna Kinderkrebsforschung	A group of chimeric antigen receptors (cars)
EP3902838A4 (en)	2018-12-26	2022-12-21	Nanjing Legend Biotech Co., Ltd.	Cd30-binding moieties, chimeric antigen receptors, and uses thereof
SG11202108740UA (en) *	2019-03-01	2021-09-29	Nat Univ Singapore	Engineered immune cells
AU2020233284A1 (en)	2019-03-01	2021-09-16	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
AU2020237633B2 (en)	2019-03-08	2025-08-28	Klinikum Der Universität München	CCR8 expressing lymphocytes for targeted tumor therapy
CN111254157A (zh) *	2019-06-06	2020-06-09	南京艾德免疫治疗研究院有限公司	靶向人源化cd30的嵌合抗原受体及其用途
CA3153197A1 (en)	2019-10-03	2021-04-08	Ryan T. Gill	Crispr systems with engineered dual guide nucleic acids
CN110559430B (zh) *	2019-10-21	2023-07-11	江苏省肿瘤医院	一种抗淋巴瘤的car-t药物及其应用
EP4114449A2 (en)	2020-03-05	2023-01-11	Neotx Therapeutics Ltd.	Methods and compositions for treating cancer with immune cells
WO2021221927A1 (en)	2020-04-27	2021-11-04	Parsons Corporation	Narrowband iq signal obfuscation
US20230263890A1 (en) *	2020-06-05	2023-08-24	Tessa Therapeutics Ltd.	Treatment of cd30-positive cancer
WO2022113056A1 (en)	2020-11-30	2022-06-02	Crispr Therapeutics Ag	Gene-edited natural killer cells
EP4263600A1 (en)	2020-12-18	2023-10-25	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
WO2022140388A1 (en)	2020-12-21	2022-06-30	Allogene Therapeutics, Inc.	Protease-activating cd45-gate car
KR102290335B1 (ko) *	2020-12-29	2021-08-18	주식회사 인투앱	Cd30을 표적으로 하는 키메라 항원 수용체 및 이의 용도
EP4271798A1 (en)	2020-12-30	2023-11-08	CRISPR Therapeutics AG	Compositions and methods for differentiating stem cells into nk cells
CN112725283B (zh) *	2021-01-10	2023-01-06	武汉科技大学	靶向cd30和cd24的双靶点car-t细胞的构建方法及应用
JP2024505075A (ja)	2021-01-29	2024-02-02	アロジーンセラピューティクス，インコーポレイテッド	同種細胞産物のＴ細胞認識を軽減するための、ＴＡＰ２、ＮＬＲＣ５、β２ｍ、ＴＲＡＣ、ＲＦＸ５、ＲＦＸＡＰ及びＲＦＸＡＮＫのうち１つ以上のノックダウン又はノックアウト
WO2022182801A1 (en)	2021-02-25	2022-09-01	Artisan Development Labs, Inc.	Compositions and methods for targeting, editing, or modifying genes
CA3211463A1 (en) *	2021-03-01	2022-09-09	Nantbio, Inc.	Anti-cd30 monoclonal antibodies and chimeric antigen receptors
EP4330379A2 (en)	2021-04-27	2024-03-06	Baylor College of Medicine	Virus-specific immune cells expressing chimeric antigen receptors
US20250179481A1 (en)	2021-06-01	2025-06-05	Celyntra Therapeutics Sa	Compositions and methods for targeting, editing, or modifying genes
WO2022266538A2 (en)	2021-06-18	2022-12-22	Artisan Development Labs, Inc.	Compositions and methods for targeting, editing or modifying human genes
EP4387991A1 (en)	2021-08-18	2024-06-26	Julius-Maximilians-Universität Würzburg	Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
WO2023072953A1 (en)	2021-10-26	2023-05-04	Tessa Therapeutics Ltd.	Cell lines for producing a retroviral vector encoding a car
WO2023104910A1 (en)	2021-12-08	2023-06-15	Tessa Therapeutics Ltd.	Treatment of lymphoma
WO2023167882A1 (en)	2022-03-01	2023-09-07	Artisan Development Labs, Inc.	Composition and methods for transgene insertion
KR20250024750A (ko)	2022-04-13	2025-02-19	티크바 알로셀 피티이. 엘티디.	치료용 t 세포 산물
WO2023205148A1 (en) *	2022-04-19	2023-10-26	Intellia Therapeutics, Inc.	Chimeric antigen receptor compositions and uses
AU2023312973A1 (en)	2022-07-29	2025-01-09	Allogene Therapeutics, Inc.	Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024098024A1 (en)	2022-11-04	2024-05-10	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024165024A1 (zh) *	2023-02-09	2024-08-15	星尘生物科技(上海)有限公司	一种嵌合抗原受体及其应用
US20240392023A1 (en) *	2023-05-18	2024-11-28	Abclon Inc.	Anti-cd30 antibody and chimeric antigen receptor comprising thereof
WO2025030693A1 (zh) *	2023-08-08	2025-02-13	星尘生物科技(上海)有限公司	双特异性嵌合抗原受体及其应用
WO2025096560A1 (en)	2023-10-30	2025-05-08	Allogene Therapeutics, Inc.	Engineered cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19640733A1 (de)	1996-10-02	1998-04-09	Abken Hinrich	Verfahren zur Hemmung der unbegrenzten Profileration, Tumorbildung oder Metastasierung CD30 Antigen exprimierender Zellen
DK3169703T4 (da)	2014-07-16	2024-02-26	Hinrich Abken	Kimær antigenreceptor og anvendelse deraf

2014
- 2014-08-26 ES ES14756036T patent/ES2905557T3/es active Active
- 2014-08-26 JP JP2016535506A patent/JP6285553B2/ja active Active
- 2014-08-26 WO PCT/EP2014/068029 patent/WO2015028444A1/en not_active Ceased
- 2014-08-26 EP EP21216276.2A patent/EP3995512A1/en active Pending
- 2014-08-26 DK DK14756036.1T patent/DK3039040T3/da active
- 2014-08-26 EP EP14756036.1A patent/EP3039040B1/en active Active
- 2014-08-26 US US14/912,937 patent/US10808035B2/en active Active
- 2014-08-26 CN CN201480047265.5A patent/CN105940102B/zh active Active
2020
- 2020-09-14 US US17/019,709 patent/US12404338B2/en active Active

Also Published As

Publication number	Publication date
ES2905557T3 (es)	2022-04-11
CN105940102A (zh)	2016-09-14
WO2015028444A1 (en)	2015-03-05
US20200407458A1 (en)	2020-12-31
US10808035B2 (en)	2020-10-20
US12404338B2 (en)	2025-09-02
US20160200824A1 (en)	2016-07-14
EP3039040B1 (en)	2021-12-22
JP6285553B2 (ja)	2018-02-28
EP3039040A1 (en)	2016-07-06
EP3995512A1 (en)	2022-05-11
CN105940102B (zh)	2020-02-18
JP2016528899A (ja)	2016-09-23

Publication	Publication Date	Title
DK3039040T3 (da)	2022-02-07	Kimær anti cd30-antigenreceptor og anvendelse deraf
DK3546572T3 (da)	2024-05-06	CD19-specifik kimær antigenreceptor og anvendelser deraf
DK3026062T3 (da)	2020-10-12	Anti-pd-1-antistof og anvendelse deraf
DK2956175T3 (da)	2017-11-27	Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
DK3683235T3 (da)	2024-07-08	Anti-IL-33-antistoffer og anvendelser deraf
HRP20181478T1 (hr)	2018-11-02	Humanizirani anti-cd134 (ox40) protutijela i njihove uporabe
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
SMT201800541T1 (it)	2018-11-09	Dispositivo di chiusura
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK3169703T3 (da)	2020-11-16	Kimær antigenreceptor og anvendelse deraf
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
EP3051933A4 (en)	2016-10-05	Mounting apparatus
DK3079719T3 (da)	2019-11-18	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK2951183T3 (da)	2019-06-03	Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
UA30221S (uk)	2015-09-10	Внутрішньоротовий пристрій
DK3233903T3 (da)	2021-02-22	Kimære antigenreceptorer og anvendelsesfremgangsmåder
EP2989432C0 (en)	2024-05-29	IMAGING APPARATUS AND METHOD
HRP20181561T1 (hr)	2018-11-30	Usmjerivi medicinski uređaj
DK2964374T3 (da)	2020-08-24	Synteseanordning og fremgangsmåde
DK3079743T3 (da)	2022-10-17	Anordning
DK2964767T3 (da)	2020-03-23	Toksingener og fremgangsmåder til anvendelse deraf
DK3029038T3 (da)	2019-05-27	Tetrazolinonforbindelse og anvendelse deraf
DK2767269T3 (da)	2019-05-06	Terapeutisk anordning